-
Real-World Evidence Supports Trastuzumab Deruxtecan in HER2+ Breast Cancer with Brain Metastases
In a multicenter observational study across 12 Italian oncology units, Dr. Alessandra Fabi and colleagues evaluated the real-life effectiveness of Trastuzumab Deruxtecan (T-DXd) in 39 patients with HER2-positive breast cancer…
-
Epigenetics in Breast Cancer: The Rise of Precision Medicine
Published in Breast Cancer (Springer) in June 2024,Sujata Purja, Dung Thuy Nguyen, and Eunyong Kim provide a comprehensive analysis of the evolving landscape of breast cancer epigenetics, emphasizing the therapeutic…
-
Real-World Evidence on the Hugo™ RAS System in Urologic Surgery: Global Data from 917 Patients
At EAU25, Professor Alexander Mottrie presented the latest real-world findings from one of the largest prospective series evaluating the Hugo™ Robotic-Assisted Surgery (RAS) System in urology. This international study, conducted…
-
First-in-Human RoLEP with Robotic Assistance: A New Milestone in BPH Surgery
At #EAU25, Dr. Rodrigo Ledezma and colleagues presented the first-in-human results from the ASTRA study, evaluating robotic-assisted Holmium Laser Enucleation of the Prostate (RoLEP) using the Beacon Platform.This novel robotic…
-
Real-World Eligibility in mPCa Trials: Insights from the APPLICABILITY Study Presented at EAU25
At EAU25, Dr. Francesco Pellegrino from IRCCS San Raffaele Scientific Institute presented a crucial analysis on the generalizability of randomized trials in newly diagnosed metastatic prostate cancer (mPCa). Using the…
-
APPEAL Trial: Landmark International RCT Shows Ciprofloxacin Lowers Post-SWL Infection Risk
Presented by Dr. Kari Tikkinen and team at EAU25, the APPEAL trial is the largest randomized controlled study to date evaluating the role of antimicrobial prophylaxis during shock wave lithotripsy…
-
BOND-003: Intravesical Cretostimogene Shows Durable Responses in High-Risk BCG-Unresponsive NMIBC
Presented by Dr. Trinity Bivalacqua at EAU25, the BOND-003 Phase 3 trial showcases updated data on intravesical cretostimogene grenadenorepvec, an innovative oncolytic immunotherapy for patients with high-risk BCG-unresponsive non–muscle invasive…
-
PROQURE-I: Promising Phase I Data on [¹⁷⁷Lu]Lu-PSMA-617 in Curative Treatment of N1 Prostate Cancer Presented by Dr. Lotte G. Zuur at EAU25
At #EAU25, Dr. Lotte Zuur from the The Netherlands Cancer Institute presented the first results of the PROQURE-I study, a phase I trial evaluating the addition of [¹⁷⁷Lu]Lu-PSMA-617 to standard…
Connecting Medical Expertise through Media